4D Molecular Therapeutics (FDMT) Return on Equity (2021 - 2025)
Historic Return on Equity for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to 0.53%.
- 4D Molecular Therapeutics' Return on Equity fell 2800.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year decrease of 2800.0%. This contributed to the annual value of 0.39% for FY2024, which is 200.0% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Return on Equity is 0.53%, which was down 2800.0% from 0.44% recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year Return on Equity high stood at 0.18% for Q2 2024, and its period low was 0.53% during Q3 2025.
- Over the past 5 years, 4D Molecular Therapeutics' median Return on Equity value was 0.3% (recorded in 2024), while the average stood at 0.33%.
- In the last 5 years, 4D Molecular Therapeutics' Return on Equity soared by 2600bps in 2024 and then crashed by -2800bps in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Return on Equity stood at 0.26% in 2021, then plummeted by -70bps to 0.45% in 2022, then rose by 29bps to 0.32% in 2023, then grew by 4bps to 0.3% in 2024, then plummeted by -75bps to 0.53% in 2025.
- Its Return on Equity was 0.53% in Q3 2025, compared to 0.44% in Q2 2025 and 0.36% in Q1 2025.